Montag & Caldwell LLC lowered its position in shares of Core Laboratories N.V. (NYSE:CLB) by 41.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,554 shares of the oil and gas company’s stock after selling 1,806 shares during the period. Montag & Caldwell LLC’s holdings in Core Laboratories N.V. were worth $259,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. UBS Asset Management Americas Inc. boosted its stake in Core Laboratories N.V. by 0.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 114,731 shares of the oil and gas company’s stock worth $13,772,000 after buying an additional 556 shares during the last quarter. Creative Planning boosted its stake in Core Laboratories N.V. by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock worth $200,000 after buying an additional 33 shares during the last quarter. Gulf International Bank UK Ltd boosted its stake in Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares during the last quarter. Bank of Montreal Can boosted its stake in Core Laboratories N.V. by 462.4% in the first quarter. Bank of Montreal Can now owns 163,920 shares of the oil and gas company’s stock worth $18,937,000 after buying an additional 134,773 shares during the last quarter. Finally, Atria Investments LLC boosted its stake in Core Laboratories N.V. by 11.2% in the first quarter. Atria Investments LLC now owns 3,839 shares of the oil and gas company’s stock worth $443,000 after buying an additional 388 shares during the last quarter.

Shares of Core Laboratories N.V. (CLB) opened at 92.92 on Friday. The company has a 50-day moving average of $101.46 and a 200 day moving average of $108.84. Core Laboratories N.V. has a one year low of $92.81 and a one year high of $125.83. The stock has a market cap of $4.10 billion, a PE ratio of 57.01 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The business had revenue of $163.90 million for the quarter, compared to analyst estimates of $168.23 million. During the same quarter in the prior year, the business posted $0.35 EPS. Core Laboratories N.V.’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, analysts predict that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 14th. Shareholders of record on Monday, July 17th will be paid a dividend of $0.55 per share. The ex-dividend date is Thursday, July 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.37%. Core Laboratories N.V.’s payout ratio is 134.15%.

COPYRIGHT VIOLATION WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://theolympiareport.com/2017/08/12/core-laboratories-n-v-nyseclb-position-lowered-by-montag-caldwell-llc.html.

CLB has been the topic of a number of recent analyst reports. Loop Capital upgraded shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and increased their price target for the company from $125.00 to $130.00 in a report on Friday, April 21st. Zacks Investment Research upgraded shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, April 21st. ABN Amro upgraded shares of Core Laboratories N.V. to a “hold” rating in a report on Friday, April 21st. Scotiabank set a $136.00 price target on shares of Core Laboratories N.V. and gave the company a “hold” rating in a report on Saturday, April 22nd. Finally, ValuEngine cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.